Searchable abstracts of presentations at key conferences in endocrinology

ea0081p306 | Calcium and Bone | ECE2022

Effects on bone mineral density and bone markers of the sequential treatment with teriparatide followed by zoledronic acid in patients with severe fractured osteoporosis: retrospective real-life data

Dito Giorgia , Degradi Chiara , Guabello Gregorio , Longhi Matteo , Corbetta Sabrina

Osteoporosis is a chronic condition requiring long-term treatment; sequential treatment regimens with different agents represents an option aimed to increase bone mineral density (BMD) and then to maintain it. The loss of BMD occurring after withdrawal of teriparatide (TPT) can be prevented by bisphosphonates (BPs). Among BPs, data about the efficacy of zoledronic acid (ZOL) after TPT treatment are scanty. Here, we contribute to this topic providing data derived from the real-...

ea0081ep162 | Calcium and Bone | ECE2022

Hypophosphatemia in patients with primary hyperparathyroidism

Amodeo Alessandro , Dito Giorgia , Guabello Gregorio , Longhi Matteo , Corbetta Sabrina

Osteoporosis management increased determination of serum calcium (Ca) levels, and detection of hypercalcemia in the set of out patients. Serum phosphate (P) levels are less frequently measured in osteometabolic patients. Primary hyperparathyroidism (PHPT) is the most common cause of hypophosphatemia. However, hypophosphatemia receives poor attention during the PHPT diagnostic work up, and also data in literature are scanty. We retrospectively reviewed the clinical records from...

ea0073aep131 | Calcium and Bone | ECE2021

Hypercalciuria and associated mineral metabolism disorders in osteopenic/osteoporotic patients: effects of treatment with thiazide diuretics

Nicoli Federico , Dito Giorgia , Guabello Gregorio , Longhi Matteo , Corbetta Sabrina

Hypercalciuria may represent a challenge during the workup for osteoporosis management. The present study aimed: 1) to describe the phenotype associated with hypercalciuria in vitamin D-repleted (serum 25OHD > 20 ng/ml) osteopenic/osteoporotic patients, focusing on kidney, bone and mineral metabolic features; 2) to analyze the effects of thiazides and anti-resorptive drugs on urine calcium excretion (UCa) and mineral metabolism markers. Seventy patients (67 postmenopausal ...

ea0070aep199 | Bone and Calcium | ECE2020

Biochemical and clinical findings distinguishing between the genetic and the acquired conditions in osteoporotic patients with low serum alkaline phosphatase levels

Sileo Federica , Guarnieri Vito , Indirli Rita , Guabello Gregorio , Longhi Matteo , Dito Giorgia , Corbetta Sabrina

Background: Hypophosphatasia is a rare genetic disease with low serum alkaline phosphatase (ALP) activity and hypophosphatasemia. It is caused by loss-of-function mutations and deletions of the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP) gene; it has a wide range of severity in its phenotype, from death in utero to asymptomatic disease accidentally diagnosed in adult life. Furthermore, some diseases and drugs may induce hypophosphatasemia. Thus, the ...

ea0037gp.10.09 | Calcium, Vitamin D and Bone | ECE2015

Serum cystatin C levels were correlated with cardiometabolic features and cardiovascular diseases in patients with primary hyperparathyroidism

Verdelli Chiara , Ermetici Federica , Filopanti Marcello , Verga Uberta , Passeri Elena , Dito Giorgia , Malavazos Alexis Elias , Mapelli C , Raggi M E , Corbetta Sabrina

Patients with primary hyperparathyroidism (PHPT) are at risk of chronic kidney disease (CKD). PHPT patients (n=190, 146 females and 44 males, aged 59.7±14.2 years) and non-hypertensive, non-diabetic age- and sex-matched healthy controls were evaluated for serum cystatin C and creatinine. PHPT patients and controls with established CKD were excluded. Serum cystatin C was measured by immunonephelometric assay and calculation of estimated glomerular filtration rate ...